Compositions and methods for treating multiple sclerosis and related disorders
The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating multiple sclerosis and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.
1. A method for treating multiple sclerosis in a human subject in need thereof, said method comprising orally administering to said human subject an effective amount of a therapeutic composition comprising live non-pathogenic fecal bacteria and a non-cellular fecal filtrate.
2. The method of claim 1 , wherein said multiple sclerosis is selected from the group consisting of clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), and secondary progressive multiple sclerosis (SPMS).
3. The method of claim 1 , wherein said therapeutic composition comprises non-selected fecal microbiota.
4. The method of claim 3 , wherein said fecal microbiota comprise a donor's entire fecal microbiota.
5. The method of claim 3 , wherein said fecal microbiota are from synthetic fecal material.
6. The method of claim 1 , wherein said method reduces the Sum8 score of said-subject by at least 10%, 20%, 30%, 50%, 60%, 70%, 80%, or 90% after at least 8 weeks of treatment.
7. The method of claim 1 , wherein said therapeutic composition is administered at least once daily for at least 2 weeks.
8. The method of claim 1 , wherein said therapeutic composition is administered at least twice weekly for at least two weeks.
9. The method of claim 8 , wherein said therapeutic composition is administered at least twice weekly for at least 4 weeks.
10. The method of claim 8 , wherein said therapeutic composition is administered at least twice weekly for at least 8 weeks.
11. The method of claim 1 , wherein said therapeutic composition is administered at least three times weekly for at least 4 weeks.
12. The method of claim 1 , wherein said method comprises a first dosing schedule followed by a second dosing schedule, wherein said second dosing schedule comprises a maintenance dose lower than or equal to the dose of said first dosing schedule.
13. The method of claim 1 , wherein said therapeutic composition is formulated as a delayed or gradual enteric release form.
14. The method of claim 1 , wherein said therapeutic composition is formulated as an enteric coated capsule or an acid-resistant capsule.
15. The method of claim 1 , wherein said therapeutic composition comprises from 10 8 to 10 14 cfu or total number of cells.
16. The method of claim 1 , wherein said therapeutic composition is in a liquid, frozen, freeze-dried, spray-dried, foam-dried, or powder form.
17. The method of claim 1 , wherein said therapeutic composition comprises a cryoprotectant selected from the group consisting of polyethylene glycol, skim milk, erythritol, arabitol, sorbitol, glucose, fructose, alanine, glycine, proline, sucrose, lactose, ribose, trehalose, dimethyl sulfoxide (DMSO), glycerol, and a combination thereof.
18. The method of claim 1 , wherein said method reduces one or more symptoms selected from the group consisting of constipation and stool leakage, difficulty urinating, frequent urination, urine leakage, double vision, eye discomfort, rapid eye movements, vision loss, memory loss, difficulty solving problems, depression, hearing loss, slurred speech, difficulty with chewing and difficulty with swallowing, limb weakness, tremors, numbness, and motor difficulties.
19. A method for treating multiple sclerosis in a human subject in need thereof, said method comprising orally administering to said human subject an effective amount of a therapeutic composition comprising live non-pathogenic fecal bacteria, wherein said human subject in need thereof is pretreated with an antibiotic prior to administration of said therapeutic composition.
20. The method of claim 19 , wherein said multiple sclerosis is selected from the group consisting of clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), and secondary progressive multiple sclerosis (SPMS).
21. The method of claim 19 , wherein said therapeutic composition comprises non-selected fecal microbiota.
22. The method of claim 21 , wherein said fecal microbiota comprise a donor's entire fecal microbiota.
23. The method of claim 21 , wherein said fecal microbiota are from synthetic fecal material.
24. The method of claim 19 , wherein said method reduces the Sum8 score of said subject by at least 10%, 20%, 30%, 50%, 60%, 70%, 80%, or 90% after at least 8 weeks of treatment.
25. The method of claim 19 , wherein said therapeutic composition is administered at least once daily for at least 2 weeks.
26. The method of claim 19 , wherein said therapeutic composition is administered at least twice weekly for at least two weeks.
27. The method of claim 21 , wherein said therapeutic composition is administered at least twice weekly for at least 4 weeks.
28. The method of claim 21 , wherein said therapeutic composition is administered at least twice weekly for at least 8 weeks.
29. The method of claim 19 , wherein said therapeutic composition is administered at least three times weekly for at least 4 weeks.
30. The method of claim 19 , wherein said method comprises a first dosing schedule followed by a second dosing schedule, wherein said second dosing schedule comprises a maintenance dose lower than or equal to the dose of said first dosing schedule.
31. The method of claim 19 , wherein said therapeutic composition is formulated as a delayed or gradual enteric release form.
32. The method of claim 19 , wherein said therapeutic composition is formulated as an enteric coated capsule or an acid-resistant capsule.
33. The method of claim 19 , wherein said therapeutic composition comprises from 10 8 to 10 14 cfu or total number of cells.
34. The method of claim 19 , wherein said therapeutic composition is in a liquid, frozen, freeze-dried, spray-dried, foam-dried, or powder form.
35. The method of claim 19 , wherein said therapeutic composition comprises a cryoprotectant selected from the group consisting of polyethylene glycol, skim milk, erythritol, arabitol, sorbitol, glucose, fructose, alanine, glycine, proline, sucrose, lactose, ribose, trehalose, dimethyl sulfoxide (DMSO), glycerol, and a combination thereof.
36. The method of claim 19 , wherein said method reduces one or more symptoms selected from the group consisting of constipation and stool leakage, difficulty urinating, frequent urination, urine leakage, double vision, eye discomfort, rapid eye movements, vision loss, memory loss, difficulty solving problems, depression, hearing loss, slurred speech, difficulty with chewing and difficulty with swallowing, limb weakness, tremors, numbness, and motor difficulties.